Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S.
Nuciforo P, et al. Among authors: werutsky g.
Eur J Cancer. 2023 Mar;181:92-101. doi: 10.1016/j.ejca.2022.12.020. Epub 2022 Dec 27.
Eur J Cancer. 2023.
PMID: 36641898
Clinical Trial.